NantWorks, Inc. and Sorrento Therapeutics, Inc. have entered a collaboration agreement to discover and develop anti-cancer immunotherapies from Sorrento’s G-MAB library against neoepitopes of tumor-specific antigens discovered using NantWorks’ pan-omics based, precision medicine approach.   NantCell, LLC, a NantWorks company, will have exclusive license to certain antibodies and CAR-TNK products in exchange for $10 million in cash and $100 million in NantCell’s equity. Sorrento...